Latest Conference Articles

March 17th 2021, 9:04pm

EBMT Meeting

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

March 16th 2021, 10:15pm

EBMT Meeting

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

March 16th 2021, 10:12pm

EBMT Meeting

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

March 16th 2021, 8:15pm

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

March 16th 2021, 7:13pm

EBMT Meeting

Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

March 16th 2021, 6:24pm

EBMT Meeting

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

March 16th 2021, 2:00pm

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

March 16th 2021, 1:26am

HCC-TAG Conference

Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.

March 15th 2021, 10:10pm

EBMT Meeting

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

March 15th 2021, 9:55pm

EBMT Meeting

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

March 15th 2021, 9:06pm

EBMT Meeting

Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.

March 15th 2021, 8:58pm

EBMT Meeting

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

March 15th 2021, 8:43pm

Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.

March 15th 2021, 6:05pm

EBMT Meeting

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

March 13th 2021, 1:30pm

PER® New York GU

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

March 12th 2021, 11:14pm

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

March 10th 2021, 9:35pm

HCC-TAG Conference

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

March 8th 2021, 7:00pm

PER® Miami Breast Cancer Conference

Olaparib and talazoparib failed to demonstrate statistically significant improvements in overall survival compared with chemotherapy in pretreated patients with BRCA1/2-mutant metastatic HER2-negative breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control

March 7th 2021, 7:12pm

PER® Miami Breast Cancer Conference

One year into the COVID-19 pandemic has allowed for some reflection on the different evolutions that the oncology community went through in response to the many challenges posed by the virus.

March 7th 2021, 3:59pm

PER® Miami Breast Cancer Conference

Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.